MLH1 and cancer: As indicated above, even the detection of MLH1 promoter hypermethylation or of a BRAF mutation (in CRC) does not exclude definitively the possibility of LS, and it remains important to consider the results in light of the clinical data, i.e., the patient’s personal and family history of cancers.